Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients

NCT00608868 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00608868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00608868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multicenter, Non-randomized, Open-labeled Study to Evaluate the Efficacy of Gefitinib (IRESSA®) as a Second-line Therapy in NSCLC Patients
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2007
Completion date
January 31, 2009
Enrollment
156 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung carcinoma